Related Experiment Videos
In vitro activity of LY127935
Antimicrobial Agents and Chemotherapy
|September 1, 1979
Summary
LY127935, a novel beta-lactam antibiotic, shows potent in vitro activity against common gram-negative bacilli and Bacteroides fragilis. This new antibiotic demonstrates significant potential against resistant bacterial strains.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Emerging antibiotic resistance poses a significant threat to public health.
- Novel antimicrobial agents are crucial for combating resistant bacterial infections.
- Facultative gram-negative bacilli, Staphylococcus aureus, and Bacteroides fragilis are common causes of infection.
Purpose of the Study:
- To evaluate the in vitro antimicrobial activity of LY127935.
- To compare the efficacy of LY127935 against other antibiotics.
- To assess the activity of LY127935 against clinically relevant, resistant bacterial isolates.
Main Methods:
- In vitro susceptibility testing was performed.
- Minimum inhibitory concentrations (MICs) were determined.
- Activity was assessed against recent clinical isolates of gram-negative bacilli, S. aureus, and B. fragilis.
Main Results:
- LY127935 demonstrated potent activity against Escherichia coli, Klebsiella pneumoniae, Enterobacter sp., Proteus sp., Serratia marcescens, and B. fragilis (median MICs ≤ 1.0 µg/ml).
- It showed good activity against S. aureus and moderate activity against Pseudomonas aeruginosa.
- LY127935 was more potent than cefamandole, cefoxitin, and piperacillin, and comparable to tobramycin and amikacin against most tested species.
Conclusions:
- LY127935 exhibits broad-spectrum in vitro activity, particularly against challenging gram-negative pathogens.
- Its efficacy against resistant strains suggests potential clinical utility.
- LY127935 represents a promising novel beta-lactam antibiotic for treating bacterial infections.